<?xml-stylesheet type='text/xsl' href='rsspretty.xsl' version='1.0'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <atom:link href="http://www.law360.com/company_articles/2121" rel="self" type="application/rss+xml"/>
    <title>Law360: Johnson &amp; Johnson</title>
    <link>http://www.law360.com/</link>
    <description>Latest articles for organization: Johnson &amp; Johnson</description>
    <copyright>Copyright 2009 Portfolio Media, Inc.</copyright>
    <language>en-US</language>
    <image>
      <url>http://www.law360.com/images/headings/logo.gif</url>
      <title>Law360</title>
      <link>http://www.law360.com/</link>
    </image>
    <item>
      <title>Pfizer Hit With $6.3M Prempro Verdict In Pa.</title>
      <link>http://www.law360.com/articles/135646</link>
      <description>A Pennsylvania jury has ruled that two Pfizer Inc. units are on the hook for at least $6.3 million in compensatory damages to an Illinois woman who developed breast cancer after she began taking popular menopause drugs Prempro and Provera.</description>
      <guid>http://www.law360.com/articles/135646</guid>
    </item>
    <item>
      <title>EU To Request Drug Patent Deal Details</title>
      <link>http://www.law360.com/articles/135185</link>
      <description>The head of the European Commission's pharmaceutical task force reportedly told drug companies Thursday of plans to ask for details on patent deals with generic-drug makers that are suspected of delaying the entry of cheaper drugs into the market.
</description>
      <guid>http://www.law360.com/articles/135185</guid>
    </item>
    <item>
      <title>Class Cert. Bid Nixed In J&amp;J Panacryl Sutures MDL</title>
      <link>http://www.law360.com/articles/134403</link>
      <description>The judge overseeing multidistrict products liability litigation against Johnson &amp; Johnson rejected a request to certify a nationwide class of patients who claim they suffered infections and other complications after undergoing surgical procedures that involved allegedly defective Panacryl sutures.  </description>
      <guid>http://www.law360.com/articles/134403</guid>
    </item>
    <item>
      <title>J&amp;J Appeals Loss In CIBA Contact Lens Patent Suit</title>
      <link>http://www.law360.com/articles/134293</link>
      <description>Johnson &amp; Johnson Vision Care Inc. is planning to appeal a ruling that upheld the validity of several patents held by rival CIBA Vision Corp. and found that Acuvue Oasys With Hydraclear Plus silicone hydrogel contact lenses infringe two of the patents.</description>
      <guid>http://www.law360.com/articles/134293</guid>
    </item>
    <item>
      <title>Arthrex Hit With Patent, Trade Secrets Claims</title>
      <link>http://www.law360.com/articles/133946</link>
      <description>Surgical equipment maker Arthrex Inc. has been hit with a patent infringement suit over an instrument that was allegedly based on misappropriated trade secrets by a former employee of plaintiff MicroAire Surgical Instruments LLC.</description>
      <guid>http://www.law360.com/articles/133946</guid>
    </item>
    <item>
      <title>Endo To Pay $23M To Settle Patent Suit Over Patch</title>
      <link>http://www.law360.com/articles/133738</link>
      <description>Endo Pharmaceuticals Inc. announced Wednesday that it would pay patent-holding company LecTec Corp. $23 million to settle a suit that accused the drugmaker of infringing two patents related to adhesive patches. </description>
      <guid>http://www.law360.com/articles/133738</guid>
    </item>
    <item>
      <title>$1.7B Centocor Patent Award Against Abbott Stands</title>
      <link>http://www.law360.com/articles/132584</link>
      <description>A federal judge has upheld a jury verdict awarding Johnson &amp; Johnson subsidiary Centocor Ortho Biotech Inc. and New York University a record $1.67 billion for their claims that Abbott Laboratories' flagship arthritis drug Humira infringed their patent. </description>
      <guid>http://www.law360.com/articles/132584</guid>
    </item>
    <item>
      <title>Troutman Atty Tagged In $50M Omnicare Scheme</title>
      <link>http://www.law360.com/articles/132544</link>
      <description>The U.S. Department of Justice has named Leonard Grunstein, head of two real estate practice groups at Troutman Sanders LLP, as a defendant in a civil complaint in the still-unfolding case involving nursing home drug supply giant Omnicare Inc., which agreed Tuesday to pay $98 million to settle claims that it was part of a broad kickback scheme.</description>
      <guid>http://www.law360.com/articles/132544</guid>
    </item>
    <item>
      <title>Pfizer Prempro Verdict Rumored To Be $75M</title>
      <link>http://www.law360.com/articles/132433</link>
      <description>While the verdict officially remains under wraps, word is spreading that a Pennsylvania jury has ordered Pfizer Inc. to fork over $75 million in punitive damages to a woman who developed invasive breast cancer after she began taking the popular menopause drug Prempro.
</description>
      <guid>http://www.law360.com/articles/132433</guid>
    </item>
    <item>
      <title>Commerce Hails White House Pick For Export Post</title>
      <link>http://www.law360.com/articles/132248</link>
      <description>The U.S. Department of Commerce is lauding the White House's recent pick of Suresh Kumar to the post of director general of the U.S. and Foreign Commercial Service. 
</description>
      <guid>http://www.law360.com/articles/132248</guid>
    </item>
    <item>
      <title>Differential Diagnosis &#8212; Trending Toward Exclusion</title>
      <link>http://www.law360.com/articles/131855</link>
      <description>The recent decisions in Perry v. Novartis and Zandi v. Wyeth signify a trend toward courts excluding unreliable expert witness testimony based on differential diagnosis in toxic tort cases. More significantly, the cases articulate the inherent unreliability of differential diagnosis analysis when an alleged injury likely arises from unknown causes, say Kimberly Beck, K.C. Green and Gabrielle Hils of Dinsmore &amp; Shohl LLP.</description>
      <guid>http://www.law360.com/articles/131855</guid>
    </item>
    <item>
      <title>Tender Offer Makes A Comeback</title>
      <link>http://www.law360.com/articles/130699</link>
      <description>Once on its way to becoming a deal structure relic, the friendly tender offer is back in vogue, with deal makers increasingly dusting off the strategy and becoming reacquainted with its particular charms as well as its potential complications.</description>
      <guid>http://www.law360.com/articles/130699</guid>
    </item>
    <item>
      <title>Omnicare, Teva Unit End Kickback Claims For $112M</title>
      <link>http://www.law360.com/articles/132144</link>
      <description>Nursing home pharmacy giant Omnicare Inc. has agreed to shell out $98 million and a Teva Pharmaceutical Industries Ltd. unit has agreed to pay $14 million to settle claims that they were part of a wide-scale kickback conspiracy.</description>
      <guid>http://www.law360.com/articles/132144</guid>
    </item>
    <item>
      <title>SEC Drops Insider Trading Case Over J&amp;J Deal</title>
      <link>http://www.law360.com/articles/131900</link>
      <description>Following a mistrial, the U.S. Securities and Exchange Commission has dropped a suit against the head of a medical device company accused of trading on inside knowledge of Johnson &amp; Johnson&#8217;s acquisition of diabetes products manufacturer Animas Corp.</description>
      <guid>http://www.law360.com/articles/131900</guid>
    </item>
    <item>
      <title>Wyeth, Amgen Face Patent Suit Over Enbrel</title>
      <link>http://www.law360.com/articles/131010</link>
      <description>A British charitable trust has slapped Amgen Inc. and Pfizer Inc. subsidiary Wyeth with a lawsuit over the lucrative rheumatoid arthritis drug Enbrel, accusing the two defendants &#8212; which co-market Enbrel in the U.S. &#8212; of willfully infringing a single patent and ignoring demands for royalty payments. </description>
      <guid>http://www.law360.com/articles/131010</guid>
    </item>
    <item>
      <title>Medical Supplier Settles J&amp;J OneTouch Counterfeit Suit</title>
      <link>http://www.law360.com/articles/130534</link>
      <description>Another defendant has settled with Johnson &amp; Johnson in a sprawling trademark case accusing more than 100 companies and individuals of participating in a scheme to sell counterfeit boxes of J&amp;J's LifeScan OneTouch blood glucose test strips.</description>
      <guid>http://www.law360.com/articles/130534</guid>
    </item>
    <item>
      <title>Wyeth Hit With Punitive Damages In Prempro Case</title>
      <link>http://www.law360.com/articles/130536</link>
      <description>In a one-two punch to Pfizer Inc., a Philadelphia jury has reportedly awarded punitive damages in addition to $3.7 million in compensatory damages to a woman who developed invasive breast cancer after she began taking Prempro, which is made by the company&#8217;s Wyeth unit.</description>
      <guid>http://www.law360.com/articles/130536</guid>
    </item>
    <item>
      <title>Wyeth, Cordis Ask To Boot Boston Scientific Stent Case</title>
      <link>http://www.law360.com/articles/130360</link>
      <description>Wyeth Inc. and Cordis Corp. have asked a judge to dismiss or transfer a declaratory judgment suit filed by Boston Scientific Corp. in a fight over a patent related to drug coatings in stents, saying a suit they filed earlier elsewhere should take precedence.</description>
      <guid>http://www.law360.com/articles/130360</guid>
    </item>
    <item>
      <title>Guidant Investors Lose Bid To Revive Class Action</title>
      <link>http://www.law360.com/articles/129650</link>
      <description>Guidant Corp. has prevailed in a challenge by investors to the dismissal of a putative securities class action that alleged the medical device maker glossed over problems with its defibrillators and their impact on its aborted merger with Johnson &amp; Johnson, leading to billions of dollars in shareholder losses.</description>
      <guid>http://www.law360.com/articles/129650</guid>
    </item>
    <item>
      <title>Mylan, Others To Pay $124M Over Medicaid Rebates</title>
      <link>http://www.law360.com/articles/129135</link>
      <description>Mylan Inc. and several other pharmaceutical companies will pay a combined sum of $124 million to settle allegations that they bilked state Medicaid programs of millions of dollars by improperly classifying certain drugs for rebate purposes.</description>
      <guid>http://www.law360.com/articles/129135</guid>
    </item>
  </channel>
</rss>
